Sign in
Taking people in ChinaPhase 3

Tests extra chemotherapy after first treatment in adults with advanced ovarian cancer

Tests extra chemotherapy after first treatment in adults with advanced ovarian cancer.

Key facts

Who runs it
Fudan University
Where
Shanghai, ChinaSee the site
Trial code
Registry title
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Status
Recruiting
Phase
Phase 3
People taking part
590 people, planned
Started
8 Oct 2021
Expected to end
Sept 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
Record updated
27 July 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18-75 with stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer. The tumour must have normal BRCA1/2 genes, and the cancer must be in complete remission after surgery and first chemotherapy.

Age
18 to 75 years
Sex
Women only
Disease stage
Epithelial ovarian, fallopian tube or primary peritoneal cancer, FIGO2018 stage III or IV. Complete remission after treatment and normal CA125.
Earlier treatment
Must have had optimal cytoreductive surgery with residual tumour of 1cm (0.4 in) or less, and no more than 9 cycles of paclitaxel plus platinum chemotherapy. The last chemotherapy was no more than 8 months ago.
Biomarker or test result
Tumour BRCA1/2 wild type, shown by a qualified centre test.

Main reasons for not taking part

  • Primary or secondary immune deficiency
  • A second primary cancer, with a few exceptions
  • Severe heart, lung, liver or kidney failure
  • Uncontrolled or active infection
  • Mucinous adenocarcinoma or low grade carcinoma

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Female patients 18-75 years of age
  • ECOG 0-2
  • Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer
  • FIGO2018 stage III/IV,
  • Patients should have received optimal cytoreductive surgery with residual tumor ≤ 1cm and no more than 9 cycle paclitaxel + platinum chemotherapy achieved complete remission (accessed ) and normal CA125
  • No more than 8 months after the last chemotherapy
  • Adequate bone marrow and hepatic function at Screening:
  • Hemoglobin ≥9 g/dL
  • White blood cell count ≥3.0 × 109/L
  • Absolute neutrophil count ≥1.5 × 109/L
  • Platelet count ≥100 × 109/L
  • AST (SGOT)/ALT (SGPT) ≤2.5 ULN
  • Bilirubin <1.5 × ULN
  • Creatinine <1.5 × ULN
  • Ability and willingness to give written informed consent
  • Tumor BRCA1/2 wilde type (qualified center test)

Who cannot take part

  • Receipt of any other investigational medicinal product within the last 30 days before randomization
  • Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥ 5 years
  • Receipt of pelvic or abdominal radiotherapy
  • Any uncontrolled medical condition that may put the patient at high risk during treatment
  • Severe heart/ lung/ liver/ kidney failure
  • uncontroled or active infection disease
  • Primary or secondary immune deficiency
  • Legal incompetence, limited legal competence, or detainment in an institution for official or legal reasons
  • Mucinous adenocarcinoma, low grade carcinoma

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in China

  • Wu XiaohuaShanghai, ChinaContact: zhong zheng, MD&PHDTaking people

About the trial

What the trial wants to find out

Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.

The 2 groups in the trial

  • Follow-upNo study treatment, for comparison

    No interevention

  • three steps chemotherapyTreatment being tested

    Cyclophosphamide 400mg(250mg/m2)+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.

    Treatment: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III,Randomized, Multi-center, Open Label Study of Adjuvant Chemotherapy of Three-step Regimens (ACTS) in BRCA1/2 Wide-type Stage III and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
Plain-language title
Tests extra chemotherapy after first treatment in adults with advanced ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04520074, who can take part
Record updated
27 July 2022